哌仑西平治疗十二指肠溃疡。多中心双盲对照临床试验，两部分中的第一部分。
Pirenzepine in duodenal ulcer. A multicentre double-blind controlled clinical trial, First of two parts.
作者信息
Barbara L, Belsasso E, Bianchi Porro G, Blasi A, Caenazzo E, Chierichetti S M, Di Febo G, Di Mario F, Farini R, Giorgi-Conciato M, Grossi E, Mangiameli A, Miglioli M, Naccarato R, Petrillo M
出版信息
Scand J Gastroenterol Suppl. 1979;57:11-5.
Eighty-four patients with endoscopically-proved active duodenal ulcer were admitted to a multicentre double-blind trial with either pirenzepine tablets (25 mg three times per day for 1 week followed by 25 mg two times per day for 3 weeks) or placebo. Seventy-nine patients completed the trial, 44 treated with pirenzepine and 35 with placebo. After 4 weeks, complete healing had been achieved in 52% of the pirenzepine-treated patients and in 34% of the placebo-treated ones. Symptomatic responses were signigicantly better in those receiving pirenzepine than in those receiving placebo. In addition, the supplementary antacid consumption was significantly lesser in the pirenzepine group than in the placebo group. No important side-effects were observed in the two groups.
84例经内镜证实患有活动性十二指肠溃疡的患者被纳入一项多中心双盲试验，分别服用哌仑西平片（每日3次，每次25mg，服用1周，随后每日2次，每次25mg，服用3周）或安慰剂。79例患者完成了试验，其中44例接受哌仑西平治疗，35例接受安慰剂治疗。4周后，接受哌仑西平治疗的患者中有52%实现了完全愈合，接受安慰剂治疗的患者中这一比例为34%。接受哌仑西平治疗的患者症状缓解情况明显优于接受安慰剂治疗的患者。此外，哌仑西平组的辅助抗酸剂消耗量明显低于安慰剂组。两组均未观察到严重的副作用。
Zotero 插件